Cytokinetics, Incorporated (CYTK) Stock
Healthcare · Biotechnology · Member of Other US Stocks
Cytokinetics, Incorporated (CYTK) closed at USD 63.43 on 2026-10-14, a change of +2.4 % over the past year, with a market capitalization of USD 8.89B.
Cytokinetics, Incorporated recent closing prices
| Date | Close (USD) |
|---|---|
| 2026-10-14 | 63.43 |
| 2026-10-13 | 61.62 |
| 2026-10-12 | 62.79 |
| 2026-10-09 | 62.91 |
| 2026-10-08 | 62.01 |
| 2026-10-07 | 61.12 |
| 2026-10-06 | 61.35 |
The most recent trading day is not shown. For full charts and indicators use the analysis page.
Cytokinetics, Incorporated key figures
- Previous close
- USD 63.43 (2026-10-14)
- 1-year change
- +2.4 %
- Market cap
- USD 8.89B
- Enterprise value
- USD 9.15B
- P/E ratio (trailing)
- -8.53
- P/E ratio (forward)
- -14.38
- EPS (trailing)
- -7.49
- EPS (forward)
- -4.44
- PEG ratio
- n/a
- Price to book
- -51.14
- Revenue growth
- -57.1 %
- Earnings growth
- n/a
- Dividend per share (trailing)
- 0.00
- Short ratio
- 9.28
- Employees
- 673
- Analyst consensus (third-party)
- strong_buy
Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.
About Cytokinetics, Incorporated
Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM. It also develops Aficamten, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of HCM; and omecamtiv mecarbil, a potential treatment across the continuum of care in heart failure with severely reduced ejection fraction. In addition, the company is involved in developing and Ulacamten, a novel, selective, oral, and small molecule cardiac myosin inhibitor designed to reduce the hypercontractility associated with heart failure with preserved ejection fraction in Phase 1 clinical trials; and CK-089, a fast skeletal muscle troponin activator in Phase 1 clinical trials. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.
Technical indicators and comparison
Show RSI, MACD, EMA, CCI and ADX for Cytokinetics, Incorporated and compare it with other stocks.
Analyze CYTKAll Other US Stocks stocksStock-scoring.com provides this page for information only. It is not investment advice or a recommendation to buy or sell Cytokinetics, Incorporated shares.